Literature DB >> 2580259

Treatment of proliferative diabetic retinopathy. Long-term results of argon laser photocoagulation.

H L Little.   

Abstract

Panretinal photocoagulation (PRP) is the treatment of choice for proliferative diabetic retinopathy. Indications for treatment are the presence of disc new vessels or the presence of new vessels elsewhere with hemorrhage. Rubeosis iridis and retinal neovascularization undergo involution following panretinal photocoagulation. The long-term visual results are excellent excepting for eyes with diffuse diabetic retinal ischemia. Long-term follow-up and repeat photocoagulation as needed are advised.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2580259     DOI： 10.1016/s0161-6420(85)34059-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


  5 in total

1.  Fifteen-year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study.

Authors:  G W Blankenship
Journal:  Trans Am Ophthalmol Soc       Date:  1990

Review 2.  Laser light: its nature and its action on the eye.

Authors:  F M Bessette; L C Nguyen
Journal:  CMAJ       Date:  1989-12-01       Impact factor: 8.262

3.  Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4.

Authors:  M M K Muqit; G R Marcellino; D B Henson; L B Young; G S Turner; P E Stanga
Journal:  Eye (Lond)       Date:  2011-08-05       Impact factor: 3.775

4.  Extensive argon laser photocoagulation in the treatment of proliferative diabetic retinopathy.

Authors:  G W Aylward; R V Pearson; J D Jagger; A M Hamilton
Journal:  Br J Ophthalmol       Date:  1989-03       Impact factor: 4.638

5.  Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy.

Authors:  Luke Nicholson; Roxanne Crosby-Nwaobi; Joana C Vasconcelos; A Toby Prevost; Jayashree Ramu; Amy Riddell; James W Bainbridge; Philip G Hykin; Sobha Sivaprasad
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-08-01       Impact factor: 4.799
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.